Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.
Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.
We also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.
Our successful R&D efforts are then further developed into services we offer to clients.
To investigate the efficacy of vaccines, Intravacc performs immunological research to unravel the mechanisms of action of vaccine concepts. These immunological assays are used during preclinical and clinical stages.
Our expertise includes
Want to know more? Contact us at businessdevelopment@intravacc.nl
Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. We use our own advanced technologies, such as Vero cell line and the OMV platform.
We can apply our long-standing and extensive experience in vaccine development to design rational and modelled processes together with our clients.
Using mathematical models we can safely scale from lab to commercial scale bioreactors.
Focusing on the treatment or prevention of viral diseases such as Polio, Respiratory Syncytial Virus, Enterovirus, Influenza, Rabies and Rotavirus. We have access to a qualified Vero cell line and specialized equipment to perform research for WHO, the Dutch Ministry of Health and collaborate with other parties.
Focusing on Conjugate vaccine technology (for vaccines for Hib and Shigella) and Outer Membrane Vescicles (OMV) technology (Pertussis, Meningococcal B, Lyme disease and Tuberculosis research)
Main features
Intravacc offers assay development and vaccine characterization services. We specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.
Assays to prove the quality of a new vaccine
The quality is a decisive factor in the development of new vaccines. Intravacc uses multiple instructive assays and innovative techniques to guarantee the quality of intermediates and finished product. Our tests focus on the composition, concentration, efficacy, purity, safety, stability and identity of the new vaccine candidate.
Immunoassays
Molecular biology methods
Physicochemical analyses
Analytical techniques
Biological assays
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).
We have developed several new methods, some of which were accepted by the European Pharmacopoeia.
In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in an IMI-funded European consortium on consistency testing.
Research focus:
Achievements include:
Check out our factsheet on our 3R research
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.
Intravacc has years of experience in producing GMP batches for phase I and II clinical studies of viral and bacterial vaccines.
We have all the required equipment at our disposal for Upstream and Downstream Processing, including bioreactors of up to 100 liter.
This means we can offer a complete CTM production trajectory from seed lot production till released clinical batches.
Facilities
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Our inhouse clinical and regulatory scientists form part of each project team that develops a new vaccine. They offer regulatory support right from the start.
Innovative vaccines are mostly complex products for which there is often no clear regulatory guidance available. That is why our Regulatory and Clinical Affairs (RCA) team is involved in the development of these products right from the start.
By taking into consideration the regulatory restraints and requirements in an early phase of development, a lean transition to the next phase towards a marketed product can be made.
Our team provides regulatory support in vaccine development projects through early involvement, assessment of potential regulatory requirements, preparation of risk assessments and by seeking informal or formal scientific advice with national competent authorities.
Support varies from the preparation of pharmaceutical, preclinical, and clinical development plans and reports, to the submission of relevant regulatory dossiers (IMPD/IND, CTA) to health authorities.
CMC activities
Nonclinical
Clinical
Want to know more? Contact us at: businessdevelopment@intravacc.nl
We are always open to work closely together with academia, public health organizations (WHO, BMGF), and biotech and pharmaceutical companies. This way, we benefit from each other's strengths in developing and innovating vaccines.
Are you looking for an experienced partner who can take your discovery to the next level of preclinical research?
Are you looking for a partner with GMP facilities, who can produce clinical lot material for your toxicity studies and phase I/II clinical trials?
Are you looking for a partner with a patent portfolio covering a variety of vaccine leads, novel vaccine technologies and adjuvants?
We are happy to discuss these and other possibilities for collaboration and co-development.
Vaccine concepts/technologies available for licensing
Want to know more? Contact us at businessdevelopment@intravacc.nl
On 22 April 2020, Intravacc's CSO Gideon Kersten gave a webinar (in Dutch) on the development of a vaccine against COVID-19, in conjunction with the Royal Netherlands Chemical Society.
On Wednesday 22 April 2020, Intravacc, in conjunction with the Royal Netherlands Chemical Society, held a webinar 'In search of a corona vaccine'. In the webinar, Intravacc CSO Prof. dr. Gideon Kersten described what this search involves.
The webinar was held in Dutch, the slides shown are in English.
You can view the webinar by clicking on the picture below.
Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. We have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as wel as our own product pipeline and patents.
Check out our factsheet on Intravacc
Want to know more? Contact us at: businessdevelopment@intravacc.nl
News | 14-05-2020
Intravacc today announced the development of three COVID-19 vaccine concepts. These concepts are all based on Intravacc’s platform technologies, that have been proven safe in humans.
News | 14-05-2020
Intravacc werkt aan de ontwikkeling van drie coronavaccins: een noodvaccin en twee conventionele vaccins. Deze vaccins zijn gebaseerd op Intravacc’s technologieën, die bewezen veilig zijn in de mens.
News | 21-04-2020
Op woensdag 22 april 2020 om 15.00 uur presenteert Intravacc samen met KNCV het webinar: ‘De zoektocht naar een coronavaccin’ door Gideon Kersten, Chief Scientific Officer bij Intravacc.
News | 03-04-2020
Intravacc today announced the appointment of Dr. Jan Groen as its Chief Executive Officer, effective 1 May 2020.
News | 01-02-2019
Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.
News | 28-12-2018
Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.
Intravacc today announced the development of three COVID-19 vaccine concepts. These concepts are all based on Intravacc’s platform technologies, that have been proven safe in humans.
Bilthoven, The Netherlands – 08.00 CET, May 14, 2020 - Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced the development of three COVID-19 vaccine concepts. These concepts are all based on Intravacc’s platform technologies, that have been proven safe in humans.
“This global COVID19 pandemic requires an international effort to understand the complexity of the disease and to develop innovative COVID-19 emergency and conventional vaccines”, said Dr. Jan Groen CEO of Intravacc. “We also need to establish partnerships with pharma for large scale manufacturing and global distribution of these vaccines”.
To develop safe and effective COVID-19 vaccines, Intravacc is focusing on emergency and conventional vaccines. Intravacc’s emergency vaccine is designed to activate T-cell responses. This emergency vaccine would reduce mortality and morbidity and as a result reduces the pressure on the public health system. For this vaccine Intravacc uses its outer membrane vesicle (OMV) technology.
For its conventional COVID-19 vaccine Intravacc will use OMV’s as a carrier for spike proteins of the virus to induce a protective antibody response. For the third concept Intravacc’s approved Vero cell platform will be used to develop an intranasal vector vaccine based on Newcastle disease virus, that can replicate in humans but does not cause disease.
The expected development timelines for these COVID-19 vaccines to enter into phase 1 range from 9 to 21 months.
Gram-negative bacteria naturally release vesicles from their outer membrane. Outer membrane vesicles (OMVs) harbor bacterial proteins that play a role in establishing infection and survival of the bacterium within the human host. They are very suitable vaccine candidates. Genetic engineering techniques are being used to achieve the required antigenic composition, and to optimize immune modulating properties and safety. OMV’s are safe in humans and can be injected or administered needle free via the oral or intranasal route to achieve mucosal immunity. Intravacc’s OMV platform is fully scalable and allows for fast and efficient modification of antigen composition, either via genetic modification of the bacterial host or by conjugating antigens to stockpiled carrier OMVs.
Intravacc’s viral vaccine production processes is based on a cGMP-grade, regulatory approved, Vero cell line. This platform is being used for routine large-scale commercial vaccine manufacturing by clients world-wide. In addition, virus seed lots and clinical batches have regularly been produced on the Vero cells, for example Poliovirus, Enterovirus (EV71), and Respiratory Syncytial Virus (RSV).
Intravacc is one of the leading institutes for translational vaccinology. As an established R&D organization with over 100 years’ experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology all over the world. Its track record includes technology transfer of oral polio, measles, DPT, Hib and influenza vaccines. The institute has state-of-the-art research and production (GMP) facilities; its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide.
NOTE TO EDITORS
For more information, contact press.office@intravacc.nl or check our website at www.intravacc.nl
Intravacc today announced the appointment of Dr. Jan Groen as its Chief Executive Officer, effective 1 May 2020.
Bilthoven, The Netherlands – 07.00 CET, April 3, 2020 -
Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record developing viral and bacterial vaccines from discovery to lead concept to clinical phase I/II, today announced the appointment of Dr. Jan Groen as its Chief Executive Officer, effective 1 May 2020.
Dr Groen has many years of experience in Life Sciences and Biotech and holds a PhD degree in medical microbiology. Dr. Groen has held numerous executive management and board mandates in international profit and nonprofit companies and organizations. He built several successful commercial biotech companies in Europe and the US, and raised over $150 million for private and public companies.
Mr Nico Oudendijk, General Director of Intravacc said: “With Dr. Groen, we have found the right person to take Intravacc into the new phase of an independent vaccine research organization”.
Dr Groen stated: “I am delighted to join Intravacc, an institute with a tremendous track record in vaccinology. Developing and improving vaccines remains vitally important in the world today and with its unique one-stop facilities, Intravacc can be at the forefront of the (co)development of a coronavirus vaccine. I look forward to working together with the professional and highly committed staff to develop Intravacc into a successful organistation within the vaccine industry”.
About Intravacc
Intravacc is one of the leading institutes for translational vaccinology. As an established R&D organization with over 100 years’ experience in the development and optimization of vaccines and vaccine technologies. Intravacc has transferred its technology all over the world. Its track record includes technology transfer of oral polio, measles, DPT, Hib and influenza vaccines. The institute has state-of-the-art research and production (GMP) facilities; its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide. For more information please visit www.intravacc.nl
-----------------------------------------------------------------------------------------------------------
NOTE TO EDITORS
For more information, contact Mirjam Hartman, press officer: mirjam.hartman@intravacc.nl tel +31 6 11596994; www.intravacc.nl
Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.
In May 2018, the Dutch Ministry of Health, Welfare and Sport announced the start of the privatization process of the activities of Intravacc a leading organisation in the field of vaccines research & development. As the privatization is progressing, the buyer of Intravacc is expected to be announced in the second quarter of 2019.
Preparing for the privatization, Intravacc B.V., a private company with limited liability, was established today. Once the shares of Intravacc are sold to the selected buyer, Intravacc B.V. will become operational and all assets, staff, intellectual property and contracts & agreements will be transferred to the new entity. This ensures a smooth transition of the business and the knowledge base of Intravacc with no interruption in servicing current customers.
Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.
Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.
Intravacc’s unique Nonamen® technology offers a broad panel of PorA proteins inserted in so called Outer membrane vesicles (OMV) expected to induce protection against the Meningococcal B (MenB) disease. Furthermore, the Nonamen® technology can be included in a Meningitis combination vaccine.
Under the agreement, both parties will collaborate to establish the development of an efficacious vaccine against prevalent Men B serotypes in China.
“We are very happy to partner with CDBIO and to be able to expand the global reach of our Nonamen technology. We trust this will help to prevent the occurrence of Men B in China considerably”, said Mr Nico Oudendijk, General Director of Intravacc.
Intravacc is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationeel vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheid als diverse big pharma bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.
De Vice President Business Development (VP-BD) maakt deel uit van het management team van Intravacc en rapporteert aan de CEO. De VP-BD zorgt voor het onderhoud en de acquisitie van nieuwe externe profit- en non-profitprojecten. Klanten van Intravacc zijn vaccinproducenten, kleine biotech bedrijven, universiteiten en NGO’s zoals de Wereld Gezondheidsorganisatie en de Bill & Melinda Gates Foundation. Daarnaast is de VP-BD verantwoordelijk voor strategische marketing van Intravacc.
Je bent verantwoordelijk voor het (commercieel) ontwikkelen van de internationale profit en non-profit markt, in lijn met de strategische, wetenschappelijke en commerciële behoefte van Intravacc door:
Het salaris is afhankelijk van opleiding en relevante werkervaring en is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage.
Informatie over de functie en over de selectieprocedure kan informatie worden ingewonnen bij Gideon Kersten (030-7920460) of email: gideon.kersten@intravacc.nl
Solliciteren
Ben jij op zoek naar een baan voor langere tijd? Wil jij in een bedrijf met 150 super leuke collega`s werken? Wil jij je ontwikkelen en onmisbaar maken binnen een wetenschappelijk bedrijf? Stuur je cv en brief dan naar personeelszaken@intravacc.nl en wie weet ben jij degene die wij zoeken.
Download de vacaturetekst (pdf)
Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld
At Intravacc we often have possibilities for internships for relevant MBO-, HBO-, and WO students.
The practical work of vaccine development is divided in 4 departments. Are you looking for an interesting and challenging internship? Then check below to see what each department has to offer.
If you are interested please send an email to Human Resources: personeelszaken@intravacc.nl
Make sure your email includes the following information:
We will let you know if we have availability during the time requested.
Please note that you need to be vaccinated to access the laboratories. The necessary vaccinations will be provided by Intravacc free of charge.
In this department we develop processes for the production of bacterial vaccines. Most bacterial vaccines developed by Intravacc are either outer membrane vesicles vaccines or conjugate vaccines against many different pathogenic microorganisms. During process development we focus on the cultivation of bacteria (upstream processing, USP) and the purification of the vaccine from the culture broth (downstream processing, DSP). Processes are developed and each unit operation is optimized.
To answer the research questions and to meet the deliverables you will, during your internship, work with shaker flasks and bioreactors (from 1L to 70L and multi reactor systems) for the USP. For the DSP you will work with centrifugation and filtration techniques, these include dead-end and tangential flow filtration as well as size exclusion chromatography.
For conjugation technologies you will purify polysaccharides and perform chemical reactions to conjugate these polysaccharides to carrier proteins. This work involves analytical equipment like HPLCs. The department has a state of the art laboratory well equipped for all the research performed.
We often have openings for internships in all expertises described above.
===========================================================
In this department, we design, generate and test concept vaccines. Expertise represented in the department include molecular biology, virology, bacteriology, immunology and regulatory and clinical affairs.
For vaccine design we investigate which antigens are suitable to include in a vaccine:
This information is combined to design new bacterial, viral or cellular strains using molecular biological techniques. Next, these strains are tested in production processes by the process development departments and within ECR we study the efficacy and safety of these vaccines both in vitro and in vivo, using an array of immunological techniques. Of note, we strive to design new in vitro techniques that can replace animal experiments as much as possible.
Throughout the whole vaccine chain it is important to monitor the feasibility of a concept vaccine from a technical and economical, but also from a regulatory and clinical point of view. Since the product is meant to be used in healthy people, there are many criteria to be met and it is crucial to substantiate which choices have been made and why.
At ECR we often have openings for internships related to strain design and immunology.
This department designs, develops and improves processes for production of viral vaccines. Disciplines in the department are:
This means that a broad range of internships are possible in the PDVV department. Ranging from working with cell culture using bioreactors, focusing on purification technologies using Äkta systems and in depth mathematical calculations using specialized software, but also establishing routines for various analysis methods like virus titration and ELISA. The department uses state-of the art equipment in recently renovated laboratories at BSL2/ML-II/MI-III level.
==============================================================
This department focuses on the development of analytical tests, stable formulation and appropriate methods for administration of (new) vaccines. To facilitate efforts throughout Intravacc, ADF is structured in the following expertise groups:
We often have interesting internship assignments for students.
